Impulse Control Disorders in Parkinson's Disease: An Overview of Risk Factors, Pathogenesis and Pharmacological Management

CNS Drugs. 2024 Jun;38(6):443-457. doi: 10.1007/s40263-024-01087-y. Epub 2024 Apr 13.

Abstract

Impulse control disorders in Parkinson's disease are relatively common drug-induced addictive behaviours that are usually triggered by the dopamine agonists pramipexole, ropinirole and rotigotine. This narrative review aimed to provide a comprehensive overview of the current knowledge of impulse control disorders in Parkinson's disease. We summarised the prevalence, clinical features, risk factors and potential underlying mechanisms of impulse control disorders in Parkinson's disease. Moreover, recent advances in behavioural and imaging characteristics and management strategies are discussed. Early detection as well as a tailored multidisciplinary approach, which typically includes careful adjustment of the dopaminergic therapy and the treatment of associated neuropsychiatric symptoms, are necessary. In some cases, a continuous delivery of levodopa via a pump or the dopamine D1 receptor agonist, apomorphine, can be considered. In selected patients without cognitive or speech impairment, deep brain stimulation of the subthalamic nucleus can also improve addictions. Finding the right balance of tapering dopaminergic dose (usually dopamine agonists) without worsening motor symptoms is essential for a beneficial long-term outcome.

Publication types

  • Review

MeSH terms

  • Antiparkinson Agents / administration & dosage
  • Antiparkinson Agents / adverse effects
  • Deep Brain Stimulation
  • Disruptive, Impulse Control, and Conduct Disorders* / chemically induced
  • Disruptive, Impulse Control, and Conduct Disorders* / drug therapy
  • Disruptive, Impulse Control, and Conduct Disorders* / etiology
  • Dopamine Agonists* / administration & dosage
  • Dopamine Agonists* / adverse effects
  • Dopamine Agonists* / pharmacology
  • Humans
  • Parkinson Disease* / drug therapy
  • Risk Factors

Substances

  • Dopamine Agonists
  • Antiparkinson Agents